Date published: 2025-11-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

β-defensin 43 Inhibitors

β-Defensin 43 inhibitors represent a specialized group of chemical entities designed to specifically modulate the activity of β-defensin 43, a member of the defensin family known for its role in the immune system. Defensins are small cationic peptides that are an integral part of the innate immune response in various organisms, acting primarily through their ability to disrupt microbial membranes and signal various immune responses. β-Defensin 43 is a unique defensin subtype, distinguished by its specific sequence motifs and structural properties that contribute to its distinct functional roles within the broader defensin family. Inhibitors targeting β-defensin 43 are engineered to interact directly with the peptide or its receptor interactions, thereby modifying its natural biological activity. These inhibitors are typically small molecules or peptides themselves that are structurally designed to bind to specific domains of β-defensin 43, interfering with its ability to engage with microbial membranes or immune receptors.

The design and synthesis of β-defensin 43 inhibitors require a deep understanding of the peptide's structural conformation and functional domains. Structural biology techniques such as X-ray crystallography, NMR spectroscopy, and cryo-electron microscopy are often employed to elucidate the precise binding interactions between β-defensin 43 and its inhibitors. Computational methods, including molecular docking and dynamic simulations, are used to predict the most effective binding modes and to optimize the inhibitor structures for enhanced specificity and affinity. Additionally, biophysical assays, such as surface plasmon resonance and isothermal titration calorimetry, are essential for characterizing the binding kinetics and thermodynamics of these interactions. The inhibition of β-defensin 43 activity through these specialized inhibitors provides a valuable tool for probing the peptide's role in various biological processes, including its interactions with microbial pathogens and its involvement in modulating the immune response. This detailed understanding of β-defensin 43 inhibition can offer significant insights into the broader functions and regulatory mechanisms of defensins in host defense and immunity.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$85.00
$132.00
$287.00
$495.00
$3752.00
42
(0)

EGFR kinase inhibitor disrupting the MAPK/ERK pathway. Erlotinib indirectly inhibits β-defensin 43 by interfering with the EGFR/MAPK/ERK pathway, known to modulate β-defensin 43 transcription through specific transcription factors.

PI-103

371935-74-9sc-203193
sc-203193A
1 mg
5 mg
$32.00
$128.00
3
(1)

PI3K/mTOR dual inhibitor affecting the PI3K/AKT/mTOR pathway. PI-103 indirectly suppresses β-defensin 43, as the PI3K/AKT/mTOR pathway regulates β-defensin 43 transcription through specific transcription factors.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

PI3K inhibitor disrupting PI3K/AKT signaling. LY294002 indirectly suppresses β-defensin 43, as PI3K/AKT signaling regulates β-defensin 43 transcription through specific transcription factors.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

mTOR inhibitor disrupting mTOR signaling. Rapamycin indirectly influences β-defensin 43 expression by interfering with the mTOR pathway, known to modulate β-defensin 43 transcription through specific transcription factors.

SB 202190

152121-30-7sc-202334
sc-202334A
sc-202334B
1 mg
5 mg
25 mg
$30.00
$125.00
$445.00
45
(1)

p38 MAPK inhibitor affecting the MAPK pathway. SB203580 indirectly inhibits β-defensin 43 by disrupting the p38 MAPK pathway, known to modulate β-defensin 43 transcription through specific transcription factors.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

PI3K inhibitor disrupting PI3K/AKT signaling. Wortmannin indirectly suppresses β-defensin 43, as PI3K/AKT signaling regulates β-defensin 43 transcription through specific transcription factors.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Proteasome inhibitor impacting NF-κB signaling. Bortezomib indirectly hampers β-defensin 43 expression by blocking the proteasome, affecting the degradation of IκB and subsequent NF-κB activation, a pathway known to modulate β-defensin 43 transcription through specific transcription factors.

GSK343

1346704-33-3sc-397025
sc-397025A
5 mg
25 mg
$148.00
$452.00
1
(0)

H3K27 methyltransferase inhibitor. GSK343 indirectly influences β-defensin 43 by altering histone methylation, impacting the chromatin structure and accessibility of the β-defensin 43 gene for transcription.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$149.00
$470.00
$620.00
$1199.00
$2090.00
33
(3)

HDAC inhibitor modulating chromatin structure. Trichostatin A indirectly suppresses β-defensin 43 by altering histone acetylation, influencing the accessibility of the β-defensin 43 gene for transcription.

Cisplatin

15663-27-1sc-200896
sc-200896A
100 mg
500 mg
$76.00
$216.00
101
(4)

DNA-damaging agent affecting multiple pathways. Cisplatin indirectly influences β-defensin 43 by causing DNA damage, triggering various stress response pathways that modulate β-defensin 43 transcription through specific transcription factors.